Treatment patterns, outcomes and testing in EGFRm NSCLC patients with EGFR TKI 1L across Europe (REFLECT) - REFLECT

Inclusion Criteria

• Inclusion Criteria:
• - Confirmed diagnosis of locally advanced unresectable or metastatic NSCLC;
• - Aged at least 18 years at first diagnosis of locally advanced/metastatic NSCLC;
• - Lab-confirmed EGFR mutation;
• - Received a first- or second-generation EGFR TKI as first-line treatment for advanced/metastatic disease;
• - First-line EGFR TKI (afatinib, gefitinib, erlotinib) initiated between January 1, 2015 and June 30, 2018;
• - Patients may be alive or deceased at the time of medical record review.
• Exclusion Criteria:
• - Patients enrolled at any time in an interventional clinical trial for an experimental treatment related to EGFR-mutated NSCLC;
• - Patients receiving any systemic therapy for locally advanced or metastatic NSCLC prior to first-line EGFR TKI treatment in the locally advanced/metastatic setting;
• - Missing or unknown data on any of the following key study dates:
• • Date of initial NSCLC diagnosis;
• • Date of first diagnosis of or progression to advanced/metastatic NSCLC;
• • Date of first-line EGFR TKI initiation for advanced/metastatic disease;
• • Date of death or last available follow-up.